Physician profile
John L Tiu
NPI 1942287388
$6,196.61
in general payments reported to CMS, 2019-2025
36 companies · $704 in 2025
The $704 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,714 · 2020: $298 · 2021: $353 · 2022: $412 · 2023: $1,581 · 2024: $1,135 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,420.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,026.07 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,167.37 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $367.55 | 2019-2023 | Yupelri |
| Genzyme Corporation | $353.19 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $332.73 | 2019-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.36 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $251.73 | 2019-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $168.40 | 2019 | |
| Grifols USA, LLC | $146.84 | 2024-2025 | Prolastin-C Liquid |
| Abbott Laboratories | $105.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $98.13 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $90.58 | 2023 | Sunosi |
| Electromed, INC. | $75.46 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.84 | 2023 | Glassia |
| Harmony Biosciences LLC | $65.15 | 2023-2024 | Wakix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59.82 | 2023 | Camzyos |
| Philips North America LLC | $51.86 | 2019-2025 | Vest Therapy Und |
| Sunovion Pharmaceuticals INC. | $45.02 | 2019 | |
| Eurofins Viracor, LLC | $43.95 | 2024 | |
| Csl Behring | $41.82 | 2023 | Kcentra |
| Actelion Pharmaceuticals US, INC. | $34.90 | 2024 | Opsumit |
| Zoll Respicardia, INC. | $30.86 | 2024 | Remede System |
| Vifor Pharma, INC. | $28.82 | 2025 | Zemaira |
| Polynovo North America LLC | $28.10 | 2024 | Novosorb Btm |
| Amgen INC. | $25.54 | 2024 | Tezspire |
| 3b Medical, INC. | $23.03 | 2024 | Luna |
| Fisher & Paykel Healthcare INC | $22.61 | 2023 | Fisher & Paykel Healthcare |
| Alexion Pharmaceuticals, INC. | $22.44 | 2023 | Ultomiris |
| Verona Pharma, INC. | $22.07 | 2025 | Ohtuvayre |
| Smith+Nephew, INC. | $19.55 | 2024 | Versajet |
| Covidien LP | $18.82 | 2019 | |
| United Therapeutics Corporation | $18.70 | 2019 | |
| Pfizer INC. | $18.38 | 2023 | |
| Abbvie INC. | $17.10 | 2024 | |
| W. L. Gore & Associates, INC. | $13.64 | 2023 | Gore Synecor Biomaterial |
| Shionogi INC | $13.10 | 2023 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.